Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02668653
Title Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Daiichi Sankyo Inc.
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin + Idarubicin

Cytarabine + Daunorubicin + Idarubicin + Quizartinib

Age Groups: senior | adult
Covered Countries USA | CAN

Additional content available in CKB BOOST